Krka Enjoys ‘Strongest’ Half Year, Although Prescription Stagnates
Slovenian Firm Publishes Preliminary Results
Executive Summary
Having picked up five prescription marketing authorization approvals in the first half of 2021, Slovenian generics giant Krka will be hoping to build on stagnant prescription pharmaceuticals reported in preliminary financial results.
You may also be interested in...
Krka’s Zytiga Rival Wins CHMP Nod
Krka’s generic version of Janssen’s Zytiga has garnered a positive opinion from the EMA’s CHMP, along with Pinax Pharma’s Celsunax ioflupane generic of DaTSCAN and Nova Laboratories’ hybrid Jayempi azathioprine oral suspension.
Small Cash Component Delaying Opioid Deal, Says ‘Optimistic’ Teva
Teva CEO Kåre Schultz has spoken at great length and in great detail about Teva’s ability to reach a proposed settlement in the US over allegations the firm helped fuel the opioid epidemic, revealing that a deal may be only 12 months away.
Teva Likes Biosimilar Licensing Deals As It Cuts Full-Year Sales Guidance
Teva is keeping a keen eye out for opportunities like its US biosimilars agreement with Alvotech and more recent deal with Bioeq for biosimilar Lucentis as it attempts to maintain revenues in the coming years, following a cut to full-year sales guidance for 2021.